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Intrathecal baclofen (ITB) therapy has been proven to reduce severe spasticity in cerebral palsy (CP). However, few results 
reported the objective gait pattern change after ITB bolus injection in adult ambulatory CP. We therefore evaluated ob-
servational and kinematic gait patterns at different ITB bolus injection doses. We performed a test trial of 3-day ITB bolus 
injections at doses of 12.5 μg, 25 μg, and 50 μg in ambulatory CP. We evaluated modified Ashworth scale, visual ana-
logue scale, observational gait scale, and kinematic gait analysis after ITB bolus injection. Intrathecal administration of 
low-dose baclofen 25 μg was successfully used not only for the treatment of spasticity but also for the treatment of gait 
disturbance, whereas the higher dose baclofen 50 μg induced foot drop and deteriorated gait pattern. We experienced 
dose-dependent changes in gait pattern confirmed by the observational and kinematic gait assessments after ITB bolus 
injection in adult ambulatory CP. (Brain & NeuroRehabilitation 2015; 8: 104-108)
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Introduction
Spasticity is increased muscle tone commonly accompanying neu-
rological conditions such as cerebral palsy (CP) and brain injury. 
Spasticity of lower extremities attributes to hip/knee flexed and 
toe-walking gait. This deviation of gait pattern is correlated with the 
amount of spasticity and functional level.1 For the treatment of spas-
ticity, various therapeutic options can be considered to reduce spas-
ticity and improve motor function. Although oral medications such 
as baclofen, diazepam, dantrolene, and tizanidine may help to reduce 
muscle tone, many patients experience systemic adverse events asso-
ciated with these agents. Injection of botulinum toxin, phenol, and 
alcohol may temporarily reduce spasticity, and are particularly useful 
for patients with focal spasticity. For spasticity that does not respond 
to these treatments, selective posterior rhizotomy (SPR) or intrathecal 
baclofen (ITB) therapy can be considered as therapeutic strategies. 
In addition, orthopedic surgery has an important role in the treatment 
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of the musculoskeletal deformities and contractures by muscu-
lotendinous lengthening, tendon transfer, and derotation osteotomies.2
Contrary to orthopedic surgery and SPR, ITB therapy allows for 
reversible treatment of spasticity and modulation of muscle tone to 
effectively reduce severe spasticity that is intractable to oral 
medicine.3 Before the placement of the baclofen infusion pump, a pre-
liminary test is necessary to ensure the safety, efficacy and drawbacks 
of ITB therapy in candidate patients because ITB may induce various 
adverse events such as headache, nausea, vomiting, dizziness, respi-
ratory suppression, seizure and loss of consciousness. Above all, re-
duction of spasticity by ITB bolus infusion is not always followed 
by improvement of gait function.4 In patients with ambulatory CP, 
in particular, reduction of spasticity in leg muscles may rather induce 
muscle weakness and gait disturbance.5 However, few results have 
been reported regarding the objective gait pattern changed according 
to the amount of the ITB bolus injection in adult ambulatory CP.
Here, we present dose-dependent changes in observational and 
kinematic gait patterns in an adult patient with ambulatory CP who 
underwent ITB bolus injection as a test trial for the treatment of spas-
ticity and gait disturbance, thus allowing for the prediction of how 
a patient would respond to the ITB bolus injection. This study suggests 
that ITB bolus injection can be carefully applied in adult ambulatory 
CP with spastic gait pattern.
Case Report
A 40-year-old man who was born prematurely at 27 weeks ges-
tation with a weight of 2.2 kg was diagnosed with CP spastic diplegia 
at 1 year after birth. He visited the outpatient clinic for the management 
of spasticity and gait disturbance. He also suffered from pain in the 
lower back and both posterior thighs with a visual analog scale (VAS) 
of 7 scores. Although he has been treated with motor point block and 
medial branch block, these have provided temporary improvements 
in pain. He received the treatment in the pain clinic 2 weeks before 
the ITB bolus injection.
He could walk independently and do most activities of daily living 
with modified Barthel index (MBI) of 100 scores, functional in-
dependence measure (FIM) of 126 scores, gross motor function clas-
sification system (GMFCS) level I and manual ability classification 
system (MACS) level I. However, hip internal rotated, hip flexed, 
knee flexed, ankle dorsiflexed, ankle pronated and toe-in gait pattern 
was observed with spasticity of both legs, 30 degrees of femoral ante-
version, and 40 degrees of tibial torsion. The patient has daily received 
oral medications such as baclofen 30 mg, dantrolene 75 mg, and tizani-
dine 3 mg. Lower limb spasticity became worsen when administration 
of these drugs was stopped. According to the modified Ashworth scale 
(MAS), the grade of spasticity was 1+ in both hip flexors, 1+ in left 
knee flexors, 1 in right knee flexors, 2 in left ankle plantar flexors and 
1+ in right ankle dorsiflexors (Table 2). In the manual muscle test 
(MMT), the muscle strength was 4 in both hip flexors, 3 in both hip 
extensors, 4 in both knee flexors and extensors, 3 in both ankle dorsi-
flexors, and 3 in both ankle plantar flexors.
In the kinematic gait analysis performed before the ITB bolus in-
jection, anterior pelvic tilt was increased in the sagittal plane, and pel-
vic bump sign was observed, which shows no pelvic and hip move-
ment dissociation. In the transverse plane, external rotation of the right 
pelvis and internal rotation of the left pelvis were observed. In the sag-
ittal plane, knee flexion was seen in the overall gait cycle due to the 
spasticity of the hamstring muscles (Fig. 1A).
Because this patient was considered to be a candidate for the ITB 
therapy, he was given a test dose of ITB bolus injection to assess the 
response and adverse events. Oral medications were discontinued 3 
days before the ITB test trial. On the first day of the procedure, baclofen 
12.5 μg was administered via a lumbar puncture. The patient was 
on bed rest for at least for 3 hours following the procedure. Vital signs 
such as blood pressure, heart rate, and respiratory rate, and adverse 
events were monitored after the procedure (Table 1).6 Although there 
was no improvement in terms of the MAS for grading spasticity, dis-
comforts the patient experienced at the initiation of gait were sub-
jectively improved and the pain in the lower back and posterior thigh 
were markedly reduced (Table 2). The next day, the patient received 
25 μg of ITB, and video-based observational gait analysis was per-
formed at 4 hours after the procedure. Spasticity was reduced to MAS 
grade 1 in both hip flexors and 1+ in the left ankle plantar flexors (Table 
2). On the third day, 50 μg of baclofen was administered, and ob-
servational and kinematic gait analyses were performed at 4 hours 
after the procedure. 
Briefly, observational gait scale (OGS) of each leg was assessed 
before the procedure and after the intrathecal bolus injections of 
25 μg and 50 μg baclofen, and these were compared to analyze the 
patient’s response (Table 3).7 OGS was improved with the admin-
istration of 25 μg baclofen (left 17 scores, right 16 scores) compared 
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Fig. 1. Kinematic change in gait analysis after the intrathecal bolus injection of 50 μg baclofen. When compared with before injection (A), after intrathecal bolus 
injection of 50 μg baclofen (B), pelvic anterior tilt was decreased at the sagittal plane and asymmetric pelvic rotation improved at the transverse plane. Knee flexion
was also decreased in the swing phase at the sagittal plane. However, the patient showed right foot drop and foot internal rotation was appeared after injection at
swing phase.
Table 1. Side Effects Observed During the Intrathecal Baclofen Bolus Injection
Trials
Scale Beforeinjection 1
st day 2nd day 3rd day
Baclofen dose (μg)
Muscle weakness
Somnolence, Drowsiness
Nausea, Vomiting
Headache
Dizziness
Respiratory depression
Seizure
Loss of consciousness
-
-
-
-
-
-
-
-
-
12.5
-
-
-
-
-
-
-
-
25
-
-
-
-
-
-
-
-
50
+
-
-
-
-
-
-
-
Table 2. Comparison of the Patient’s Responses to the Intrathecal Baclofen 
Bolus Injection Trials
Scale Before injection 1
st day 2nd day 3rd day
Baclofen dose (μg)
Spasticity (MAS)
  Rt. hip flexors
  Lt. hip flexors
  Rt. knee flexors
  Lt. knee flexors
  Rt. ankle PF
  Lt. ankle PF
Pain (VAS)
-
G1+
G1+
G1
G1+
G1+
G2
7
12.5
G1+
G1+
G1
G1
G1+
G2
1
25
G1
G1
G1
G1
G1+
G1+
0
50
G1
G1
G1
G1
G1+
G1+
0
MAS: Modified Ashworth scale, VAS: Visual analogue scale, PF: Plantar flex-
or, DF: Dorsiflexor.
to baseline (left 14 scores, right 15 scores). However, these gait pat-
terns were aggravated after the intrathecal bolus injection of 50 μg 
baclofen (left 16 scores, right 11 scores). In particular, kinematic gait 
analysis at 4 hours after intrathecal bolus injection of 50 μg baclofen 
showed that pelvic anterior tilt was decreased at the sagittal plane and 
asymmetric pelvic rotation improved at the transverse plane. Knee 
flexion was also decreased in the swing phase at the sagittal plane. 
However, for the right ankle joint, foot drop pattern appeared at the 
swing phase, and foot internal rotation was aggravated. Namely, ankle 
dorsiflexion weakness presented as decreased foot clearance and 
right foot internal rotation to compensate the foot drop was shown 
(Fig. 1B). 
Discussion
In patients with CP, spasticity of lower extremities frequently caus-
es deterioration of gait pattern.1 Although these may have negative 
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Table 3. Comparison of the Observational Gait Scale to the Intrathecal Baclofen Bolus Injection Trials
Gait parameter Definition
Left leg Right leg
Before 
injection 2
nd day 3rd day Before injection 2
nd day 3rd day
1.Knee position in midstance Crouch Severe ＞15
Moderate ＞10 to 15 1 1 1
Mild ＜10 2 2 2
Neutral
Mild＜5
Recurvatum Moderate 5-10
Severe ＞10
2. Initial foot contact Toe
Forefoot 1
Foot-flat 2 2 2 2 2
Heel
3. Foot contact at midstance Toe/toe (equinus)
Foot-flat/early heel rise 0
Foot-flat/no early heel rise 1 1 1 1 1
Occasional heel/foot-flat
Heel/toe (normal roll-over)
4. Timing of heel rise No heel contact (fixed equinus)
Before 25% stance (very early)
Between 25-50% (slightly early) 2
At terminal stance 3 3 3 3 3
No heel rise (after foot-flat, i.e., crouch)
5. Hindfoot at midstance Varus
Valgus 1 1 1
Neutral 2 2 2
6. Base of support Frank scissoring
Narrow base (poor knee clearance)
Wide base 2 2 2 2
Normal base (width of shoulders) 3 3
7. Gait assistive devices Walker (forward/posterior) with assistance
Walker (independent)
Crutches, sticks
None, independent for 10 m 3 3 3 3 3 3
8. Changes Worse −1
None 1 1 1
Better 2 2
Total 14 17 16 15 16 11
impacts on pain, hygiene, sleep patterns, and activities of daily living, 
oral medications and botulinum toxin injection therapy are in-
sufficient to effectively manage these symptoms in many patients 
with severe spasticity. Previous study showed that administration of 
ITB may improve motor control in patients with ambulatory CP and 
have suggested that early placement of the ITB infusion pump is re-
quired for the prevention of orthopedic deformities and joint 
contracture.8 
In this case report, we observed changes in neurological signs and 
musculoskeletal symptoms such as spasticity, pain, and gait pattern 
after intrathecal bolus injection of low-dose baclofen. This showed 
that the ITB therapy may be effective for the management of spasticity, 
chronic pain, and gait disturbance. On the other hand, considering 
that spasticity has occasionally a positive impact in the clinical field 
and that spasticity may help to stabilize gait and compensate for mus-
cle power, the reduction of spasticity is not always followed by im-
provement in function.9 Therefore, in adult ambulatory CP, it is im-
portant to test a patient’s gait pattern and functional changes with ITB 
bolus injection before the placement of the ITB infusion pump.
The patient expressed subjectively reduced muscle tone during dy-
namic gait on the first day of 12.5 μg ITB test trial, whereas there 
was no objective change in the MAS for grading spasticity. Moreover, 
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the patient was subjectively the most satisfied and spasticity was also 
objectively reduced on the second day, when 25 μg of baclofen was 
administered. However, the patient showed foot drop pattern during 
gait after injection of baclofen 50 μg. In the observational and kine-
matic gait assessments, foot drop were observed without maintenance 
of right ankle dorsiflexion during swing phase of gait cycle. 
Accordingly, the negative change of gait pattern with more than 50 
μg daily infusion dose of ITB pump could be estimated using the 
ITB bolus injection in this patient. 
Surprisingly, chronic pain in the lower back and posterior thigh im-
proved from initial VAS score 7 to VAS score 1 after the intrathecal 
bolus injection of low-dose baclofen 12.5 μg, and then resolved after 
the administration of  25 μg baclofen. This suggests that ITB therapy 
may contribute to the improvement of secondary pain by controlling 
the spasticity6 and GABA-mediated analgesic modulation.10
In summary, we estimated the response with a baclofen infusion 
pump using the test dose of ITB bolus injection in a patient with ambu-
latory CP who had spasticity, musculoskeletal pain, and gait 
disturbance. The patient was generally satisfied and felt comfortable 
walking during gait with a low-dose ITB bolus injection, namely 25 
μg baclofen. Chronic pain in the lower back and in both legs was 
also dramatically reduced. However, maintenance of ankle dorsi-
flexion during swing phase of gait cycle was difficult after the intra-
thecal bolus injection of 50 μg baclofen. This suggests that fine con-
trol of the ITB dosages is essential to optimize the degree of spasticity 
to avoid deterioration in gait pattern.
Conclusion
We experienced dose-dependent changes in gait pattern confirmed 
by the observational and kinematic gait assessments after the ITB bolus 
injection in an adult patient with ambulatory CP. Characteristically, 
intrathecal administration of the low-dose baclofen could be success-
fully used not only for the treatment of spasticity and musculoskeletal 
pain but also for the treatment of gait disturbance, whereas the higher 
dose baclofen could induce foot drop and deteriorate gait pattern and 
potentially functional deterioration in adult ambulatory CP. 
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